This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
by Zacks Equity Research
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $68.56 in the latest trading session, marking a +0.45% move from the prior day.
Gilead (GILD) Collaborates With Yuhan for NASH Candidates
by Zacks Equity Research
Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $61.88, marking a -1.68% move from the previous day.
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
by Zacks Equity Research
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
by Zacks Equity Research
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
by Zacks Equity Research
Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).
Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
by Zacks Equity Research
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
by Zacks Equity Research
Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.
Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead
by Zacks Equity Research
Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.
Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer
by Zacks Equity Research
Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.
Bristol-Myers to Sell French Consumer Health Unit for $1.6B
by Zacks Equity Research
Bristol-Myers (BMY) receives a $1.6 billion offer for its French consumer health unit from Japanese company, Taisho.
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint
by Zacks Equity Research
Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.
Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod
by Zacks Equity Research
Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.
Evofem Shares Up as Birth Control Gel Succeeds in Phase III
by Zacks Equity Research
Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.
Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer
by Zacks Equity Research
Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.
Gilead Sciences (GILD) Stock Moves -0.69%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $65.12, moving -0.69% from the previous trading session.
Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus
by Zacks Equity Research
Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.
AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
by Zacks Equity Research
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
by Kinjel Shah
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals
by Zacks Equity Research
Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.